BFC Planning’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.33K Buy
+40
New +$2.61K ﹤0.01% 2963
2025
Q4
– Sell
-250
Closed -$9.7K – 3313
2025
Q3
$9.7K Hold
250
– – ﹤0.01% 1942
2025
Q2
$7.52K Hold
250
– – ﹤0.01% 1926
2025
Q1
$7.13K Hold
250
– – ﹤0.01% 1901
2024
Q4
$8.26K Hold
250
– – ﹤0.01% 1839
2024
Q3
$9.33K Buy
+250
New +$9.12K ﹤0.01% 1785

Other funds holding SBIO

BFC Planning's SBIO Position: Q3 2026 in Review

BFC Planning opened a new position in ALPS Medical Breakthroughs ETF (SBIO) in Q3 2026: 40 shares worth $2.33K. The stake represents ﹤0.01% of the portfolio and ranks #2963 among its holdings. This is a return to the name: BFC Planning previously reported a position in SBIO as recently as Q3 2025.

BFC Planning first reported a position in SBIO in Q3 2024 and has held it in 6 quarters since. The position peaked at $9.7K in Q3 2025. 60 funds tracked by Wall St. Rank hold SBIO as of Q3 2026.

  • BFC Planning held 40 shares of ALPS Medical Breakthroughs ETF worth $2.33K as of Q3 2026.
  • ALPS Medical Breakthroughs ETF was a new BFC Planning position in Q3 2026.
  • ALPS Medical Breakthroughs ETF made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2963 holding.
  • BFC Planning first reported a position in ALPS Medical Breakthroughs ETF in Q3 2024 and has held it in 6 quarters since.
  • BFC Planning's ALPS Medical Breakthroughs ETF position peaked at $9.7K in Q3 2025.
  • 60 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.